AMPLY, an AI-driven biotechnology company, is mining genomic 'dark matter' to identify antimicrobial compounds evolved by nature to combat drug-resistant infections. Utilizing machine learning integrated with synthetic biology, their platform focuses on detecting antimicrobial peptides and RNA interference molecules hidden within vast genomic datasets. This novel approach aims to address the global antimicrobial resistance crisis by uncovering therapeutics overlooked by conventional drug discovery, leveraging evolutionary optimized molecules for enhanced efficacy and safety.